Why Does Zepbound (Tirzepatide) Cause Vomiting? The Biology Explained

What the label says about the mechanism

Zepbound is a dual incretin agonist: it binds and activates both GIP and GLP-1 receptors [1]. The label's specific gastrointestinal effect is a delay in gastric emptying, which it states is largest after the first dose and diminishes over time [1]. It does not say how much of the vomiting comes from that delay.

The label also states that Zepbound is not recommended in patients with severe gastroparesis, and reports severe gastrointestinal adverse reactions in 1.7% of patients on 5 mg, 2.5% on 10 mg and 3.1% on 15 mg, versus 1% on placebo [1].

How often vomiting happens

In the pooled Zepbound weight-management trials (up to 72 weeks; 958 on placebo, 630 on 5 mg, 948 on 10 mg and 941 on 15 mg), vomiting was reported by 2% on placebo and 8%, 11% and 13% on 5, 10 and 15 mg [1]. Any gastrointestinal adverse reaction occurred in 56% of patients on each Zepbound dose, versus 30% on placebo, and treatment discontinuation for GI adverse reactions was 1.9% on 5 mg, 3.3% on 10 mg and 4.3% on 15 mg, versus 0.5% on placebo [1].

When vomiting occurs: dose escalation

The Zepbound schedule starts at 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg steps after at least 4 weeks on the current dose; maintenance doses are 5, 10 or 15 mg once weekly, and 2.5 mg is for initiation only [1].

The label says the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time [1]. Vomiting rates were higher at 10 mg and 15 mg than at 5 mg [1].

What the label flags as serious

Acute kidney injury due to volume depletion: the label says the majority of reported events occurred in patients who had GI reactions leading to dehydration such as nausea, vomiting or diarrhea, and calls for kidney-function monitoring in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1].

Acute pancreatitis: the label says to watch for persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, the label says to discontinue Zepbound and start appropriate management [1].